EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study

Yao Xiao iD, Yuxia Wang, Jun Li, Cheng Cheng, Chunyong Song, Xin Wang, Liyuan Tao, Hongqing Zhuang iD

Cancer Communications · 2025

DOI: 10.1002/cac2.70051 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Communications, 2025. Verfasst von Yao Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Peking University Third Hospital, Beijing, P. R. China. Hauptthemen laut MEDLINE: Radiosurgery, Neoplasms, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Education, China University Industry-University-Research Innovation Fund, Ministry of Education, China University Industry‐University‐Research Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cadonilimab is a humanized immunoglobulin G1 bispecific antibody targeting programmed cell death protein 1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4). This study aimed to evaluate the safety and efficacy of stereotactic body radiotherapy (SBRT) combined with cadonilimab in patients with advanced recurrent or refractory solid tumors.

Methods

Patients with advanced solid tumors who progressed after at least two lines of systemic treatment, including immunotherapy, and were eligible for SBRT were enrolled. SBRT was administered to patients with high‐burden/symptomatic lesions in combination with intravenous cadonilimab (6 mg/kg, once every 2 weeks). The primary endpoint was safety.

Results

Sixty‐three patients were enrolled from August 28, 2022, to September 14, 2023 (median follow‐up: 9.1 months). The median prior treatment line was 3.0 (range 2.0‐4.0). Approximately 46.0% (29/63) of patients had received prior PD‐1/PD‐L1 therapy, 36.5% (23/63) and 12.7% (8/63) of patients had non‐small cell lung cancer and soft tissue sarcoma. Treatment‐related adverse events (TRAEs) occurred in 38.1% (24/63) of patients, with grade 3 TRAEs reported in 3.2% (2/63). The most common TRAEs included pain (12.7%), elevated transaminases (12.7%), pneumonia (6.4%), fatigue (6.4%), nausea (4.8%), and fever (4.8%). The objective response rate (ORR) was 23.8% (95% confidence interval [CI], 14.0%‐36.2%). The median progression‐free survival (PFS) was 7.2 months (95% CI, 6.3‐8.2 months), and the median overall survival (OS) was 10.0 months (95% CI, 7.7‐12.4 months). The 6‐month and 12‐month local control rates were 98.4% and 93.0%, respectively. In a subgroup analysis of 23 non‐small cell lung cancer patients, the ORR was 17.4% (95% CI, 5.0%‐38.8%), the median PFS was 6.9 months (95% CI, 4.7‐9.1 months), and the median OS was 9.1 months (95% CI, 7.3‐10.9 months). Multivariate analysis indicated that receiving ≥6 cycles of cadonilimab and having an Eastern Cooperative Oncology Group performance status score of 0‐1 were significantly associated with improved PFS and OS ( P < 0.05).

Conclusions

SBRT in combination with cadonilimab demonstrated manageable toxicity and promising efficacy in heavily pretreated patients with refractory solid tumors.

Trial registration

This study was retrospectively registered at ClinicalTrials.gov (NCT05915481) on August 20, 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiosurgeryNeoplasmsAntibodies, BispecificAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedProgrammed Cell Death 1 ReceptorAdultCTLA-4 AntigenAged, 80 and overImmune Checkpoint Inhibitors

Stichwörter der Autor:innen

Cadonilimabimmunotherapyrefractory solid tumorssafetystereotactic body radiotherapy

Substanzen

Programmed Cell Death 1 ReceptorAntibodies, BispecificPDCD1 protein, humanCTLA-4 AntigenAntibodies, Monoclonal, HumanizedCTLA4 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Peking University Third Hospital, Beijing, P. R. China.
  • Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, P. R. China.
  • Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, P. R. China.
  • Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, P. R. China.
  • Medical Examination Centre, Peking University Third Hospital, Beijing, P. R. China.

ORCID-Profile: Yao Xiao, Hongqing Zhuang

Förderung

  • Ministry of Education, China University Industry-University-Research Innovation Fund
  • Ministry of Education, China University Industry‐University‐Research Innovation Fund

Zitieren

APA

Xiao, Y., Wang, Y., Li, J., Cheng, C., Song, C., Wang, X., Tao, L., & Zhuang, H. (2025). Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study. Cancer Communications. https://doi.org/10.1002/cac2.70051

Vancouver

Xiao Y, Wang Y, Li J, Cheng C, Song C, Wang X, et al. Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study. Cancer Communications. 2025. doi:10.1002/cac2.70051

BibTeX
@article{Xiao2025,
  author = {Xiao, Yao and Wang, Yuxia and Li, Jun and Cheng, Cheng and Song, Chunyong and Wang, Xin and Tao, Liyuan and Zhuang, Hongqing},
  title = {Stereotactic body radiotherapy plus cadonilimab (PD‐1/CTLA‐4 bispecific antibody) as third‐line or beyond therapy for refractory solid tumors: A phase 1b study},
  journal = {Cancer Communications},
  year = {2025},
  doi = {10.1002/cac2.70051}
}
Kostenlos starten →